Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bis(fluoroalkyl) benzodiazepinone compounds, particularly (2R,3S)—N-((3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinimide and (2R,3S)—N-[(3S)-5-(3-Fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)succinimide, face stability issues due to the formation of an oily and unstable free acid intermediate, (2R)-2-(2-tert-Butoxy-2-oxoethyl)-5,5,5-trifluoropentanoic acid, which complicates synthetic processes.
Innovation Solution
The development of stable ammonium salts, such as cyclohexylammonium salts, represented by Formula (I), which provide enhanced stability for the intermediate, maintaining purity and assay over extended periods at various temperatures and humidity levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the free acid intermediate (2R)-2-(2-tert-Butoxy-2-oxoethyl)-5,5,5-trifluoropentanoic acid is used in the synthesis process, then the synthetic route can be implemented, but the intermediate is oily and unstable, leading to impurities and degradation products that interfere with chemical reactions and final product purity
Solution Approach 1:
The patent introduces a salt form of the free acid intermediate as a mediator. By converting the unstable free acid into a stable salt (e.g., ammonium salt, sodium salt, potassium salt), the intermediate gains improved stability while maintaining its reactivity for subsequent synthesis steps. The salt acts as an intermediary form that resolves the contradiction between manufacturability and reliability.
Solution Approach 2:
The patent changes the chemical parameter of the intermediate from free acid form to salt form. This parameter change fundamentally alters the physical and chemical properties of the intermediate, transforming it from an oily, unstable substance to a stable, non-oily compound that can be stored and handled without degradation, thereby resolving the stability issue while preserving synthetic utility.
2Productivity
If the free acid intermediate is used without stabilization, then the process can proceed, but prolonged stability at room temperature or higher temperatures cannot be achieved, complicating logistical requirements for synthesis, handling and transportation
Solution Approach 1:
The salt form serves as a stable intermediary that enables the intermediate to withstand prolonged storage and transportation conditions. This mediator form allows different synthetic stages to occur at different locations and times without compromising intermediate integrity, thereby supporting productive manufacturing workflows while extending storage duration.
Solution Approach 2:
The patent applies preliminary action by converting the free acid to its salt form before storage and transportation. This preliminary stabilization ensures that the intermediate is in its most stable state before being subjected to logistical challenges, allowing it to maintain purity and potency throughout extended storage periods and facilitating flexible production scheduling.
3Productivity
If the unstable free acid intermediate is used, then the synthesis can be completed, but impurities and degradation products accumulate, interfering with chemical reactions and reducing the purity of the final drug substance and product
Solution Approach 1:
The stable salt form acts as a protective intermediary that prevents the formation of degradation products during storage and handling. By maintaining the intermediate in its stable salt form throughout the synthetic process, the patent eliminates the source of impurities that would otherwise accumulate and compromise final product purity, ensuring high-quality output while maintaining synthesis completion.
Solution Approach 2:
The patent applies beforehand cushioning by stabilizing the intermediate as a salt form prior to any potential degradation occurring. This preventive measure cushions against the formation of impurities and degradation products by maintaining the intermediate in a stable state throughout storage, handling, and synthesis operations, thereby protecting final product purity from the outset.
Data Source
AI summary
The present invention provides salts represented by the structure of Formula (I): wherein Q is an ammonium cation; and processes comprising the use of the salts in the preparation of benzodiazepinone compounds, especially bis(fluoroalkyl) derivatives thereof.